MA27105A1 - Nouveaux composes - Google Patents

Nouveaux composes

Info

Publication number: MA27105A1
Authority: MA; Morocco
Prior art keywords: new compounds; compounds; new
Prior art date: 2002-03-06

Application number

MA27806A

Other languages

English (en)

Inventor

Peter Aranyi

Laszlo Balazs

Imre Bata

Sandor Batori

Eva Baronkay

Philippe Bovy

Karoly Kanai

Zoltan Kapui

Edit Suzan

Tibor Szabo

Lajos T Nagy

Katalin Urban-Szabo

Marton Varga

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-06

Filing date

2004-07-29

Publication date

2004-12-20

2004-07-29 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2004-12-20 Publication of MA27105A1 publication Critical patent/MA27105A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Immunology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Virology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Oncology (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)

MA27806A 2002-03-06 2004-07-29 Nouveaux composes MA27105A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU0200849A HUP0200849A2 (hu)	2002-03-06	2002-03-06	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra

Publications (1)

Publication Number	Publication Date
MA27105A1 true MA27105A1 (fr)	2004-12-20

Family

ID=90001540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27806A MA27105A1 (fr)	2002-03-06	2004-07-29	Nouveaux composes

Country Status (28)

Country	Link
US (3)	US7348327B2 (fr)
EP (1)	EP1487807B1 (fr)
JP (1)	JP4559737B2 (fr)
KR (1)	KR100977898B1 (fr)
CN (2)	CN1639159A (fr)
AR (1)	AR038868A1 (fr)
AT (1)	ATE443054T1 (fr)
AU (1)	AU2003209514B2 (fr)
BR (1)	BR0307960A (fr)
CA (1)	CA2475312C (fr)
DE (1)	DE60329282D1 (fr)
EA (1)	EA007410B1 (fr)
EC (1)	ECSP045274A (fr)
HR (1)	HRP20040910A2 (fr)
HU (1)	HUP0200849A2 (fr)
IL (2)	IL163286A (fr)
IS (1)	IS7434A (fr)
MA (1)	MA27105A1 (fr)
MX (1)	MXPA04008613A (fr)
NO (1)	NO20044221L (fr)
NZ (1)	NZ535662A (fr)
PL (1)	PL371099A1 (fr)
RS (1)	RS79004A (fr)
TN (1)	TNSN04141A1 (fr)
TW (1)	TWI250978B (fr)
UA (1)	UA78291C2 (fr)
WO (1)	WO2003074500A2 (fr)
ZA (1)	ZA200406467B (fr)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE370943T1 (de) *	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
HUP0202001A2 (hu) *	2002-06-14	2005-08-29	Sanofi-Aventis	DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
TW200401635A (en) *	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR20050122220A (ko)	2003-03-25	2005-12-28	다케다 샌디에고, 인코포레이티드	디펩티딜 펩티다제 억제제
WO2004098591A2 (fr)	2003-05-05	2004-11-18	Probiodrug Ag	Inhibiteurs de glutaminyl-cyclase
WO2004103993A1 (fr)	2003-05-14	2004-12-02	Syrrx, Inc.	Inhibiteurs de dipeptidyl peptidase
BRPI0413452A (pt)	2003-08-13	2006-10-17	Takeda Pharmaceutical	composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
HU227684B1 (en) *	2003-08-29	2011-11-28	Sanofi Aventis	Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1680120A2 (fr)	2003-11-03	2006-07-19	Probiodrug AG	Combinaisons utiles au traitement de troubles neuronaux
RU2385723C2 (ru) *	2003-11-17	2010-04-10	Новартис Аг	Применение ингибиторов дипептидилпептидазы iv
CA2545641A1 (fr) *	2003-11-17	2005-06-02	Novartis Ag	Utilisation de composes organiques
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
EP1713780B1 (fr)	2004-02-05	2012-01-18	Probiodrug AG	Nouveaux inhibiteurs de la glutaminyl-cyclase
HRP20120006T1 (hr) *	2004-02-05	2012-01-31	Kyorin Pharmaceutical Co.	Derivat bicikloestera
FR2870538B1 (fr) *	2004-05-19	2006-07-14	Servier Lab	Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AP2007003973A0 (en)	2004-10-12	2007-07-30	Glenmark Pharmaceuticals Sa	Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008024592A (ja) *	2005-01-28	2008-02-07	Taisho Pharmaceut Co Ltd	シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
AP2007004234A0 (en)	2005-04-22	2007-12-31	Alantos Pharm Holding	Dipeptidyl peptidase-IV inhibitors
EP1917001A2 (fr) *	2005-08-11	2008-05-07	F.Hoffmann-La Roche Ag	Composition pharmaceutique comprenant un inhibiteur de la dpp-iv
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CA2622642C (fr)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Inhibiteurs de dipeptidylpeptidase
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
US20090156465A1 (en)	2005-12-30	2009-06-18	Sattigeri Jitendra A	Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
WO2007102286A1 (fr)	2006-03-08	2007-09-13	Kyorin Pharmaceutical Co., Ltd.	Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production
CN101050194B (zh) *	2006-04-05	2013-08-21	上海恒瑞医药有限公司	双环辛烷类衍生物、其制备方法及其在医药上的用途
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2369341A3 (fr)	2006-04-11	2012-01-04	Arena Pharmaceuticals, Inc.	Procédés d'utilisation de récepteur gpr119 pour identifier les composants utiles pour augmenter la masse osseuse chez un individu
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
KR20090047458A (ko)	2006-08-08	2009-05-12	사노피-아벤티스	아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2091948B1 (fr)	2006-11-30	2012-04-18	Probiodrug AG	Nouveaux inhibiteurs de glutaminylcyclase
CN101230059B (zh) *	2007-01-23	2011-08-17	上海恒瑞医药有限公司	双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN101230058A (zh)	2007-01-23	2008-07-30	上海恒瑞医药有限公司	双环氮杂烷类衍生物、其制备方法及其在医药上的用途
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
ATE550319T1 (de)	2007-03-22	2012-04-15	Kyorin Seiyaku Kk	Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
WO2008128985A1 (fr)	2007-04-18	2008-10-30	Probiodrug Ag	Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
JP5603770B2 (ja)	2007-05-31	2014-10-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｃｒ２受容体拮抗薬およびその使用
GB0713602D0 (en) *	2007-07-12	2007-08-22	Syngenta Participations Ag	Chemical compounds
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8338450B2 (en) *	2007-09-21	2012-12-25	Lupin Limited	Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
EP2246347B1 (fr) *	2008-01-23	2016-09-28	Shanghai Hengrui Pharmaceutical Co. Ltd.	Dérivés de dicycloazaalcane, leurs procédés de préparation et utilisations médicales
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (fr)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2732984A1 (fr) *	2008-08-07	2010-02-11	Kyorin Pharmaceutical Co., Ltd.	Procede de fabrication d'un derive de bicyclo[2.2.2]octylamine
CN102186474A (zh) *	2008-08-14	2011-09-14	杏林制药株式会社	稳定的医药组合物
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010054183A2 (fr) *	2008-11-07	2010-05-14	President And Fellows Of Harvard College	Colorants, compositions et procédés d’utilisation associés
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
EA020548B1 (ru)	2008-12-19	2014-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
GB2483614B (en)	2009-06-18	2014-12-03	Lupin Ltd	2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011023754A1 (fr)	2009-08-26	2011-03-03	Sanofi-Aventis	Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
WO2011029920A1 (fr)	2009-09-11	2011-03-17	Probiodrug Ag	Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
CN107115530A (zh)	2009-11-27	2017-09-01	勃林格殷格翰国际有限公司	基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
PE20121614A1 (es)	2009-12-17	2012-12-21	Boehringer Ingelheim Int	Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011107530A2 (fr)	2010-03-03	2011-09-09	Probiodrug Ag	Nouveaux inhibiteurs
ES2481823T3 (es)	2010-03-10	2014-07-31	Probiodrug Ag	Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
WO2011127051A1 (fr)	2010-04-06	2011-10-13	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur de gpr119 et traitement de troubles associés
EP2560953B1 (fr)	2010-04-21	2016-01-06	Probiodrug AG	Inhibiteurs de glutaminyl cyclase
CA2797310C (fr)	2010-05-05	2020-03-31	Boehringer Ingelheim International Gmbh	Therapie de combinaison de l'agoniste du recepteur glp-1 et de l'inhibiteur dpp-4
JP5646736B2 (ja)	2010-05-12	2014-12-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
EP2569298B1 (fr)	2010-05-12	2015-11-25	Boehringer Ingelheim International GmbH	Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments
WO2011144501A1 (fr)	2010-05-17	2011-11-24	Boehringer Ingelheim International Gmbh	Antagonistes du récepteur ccr2 et leurs utilisations
WO2011147772A1 (fr)	2010-05-25	2011-12-01	Boehringer Ingelheim International Gmbh	Antagonistes du récepteur ccr2
EP2576538B1 (fr)	2010-06-01	2015-10-28	Boehringer Ingelheim International GmbH	Nouveaux antagonistes de CCR2
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012120053A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
WO2012120052A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120056A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (fr)	2011-03-08	2015-05-27	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (fr)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012170702A1 (fr)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
JP5786258B2 (ja)	2011-07-15	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規かつ選択的なｃｃｒ２拮抗薬
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr)	2011-09-27	2013-04-04	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013055910A1 (fr)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013170115A1 (fr)	2012-05-11	2013-11-14	Abbvie Inc.	Dérivés de pyridazine et pyridine en tant qu'inhibiteurs de nampt
EP3685839A1 (fr)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
EP4151218A1 (fr)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptine, dérivé de xanthine en tant qu'inhibiteur de dpp-4, destinée à être utilisée dans le traitement de sirs et/ou de sepsis
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014000629A1 (fr) *	2012-06-25	2014-01-03	广东东阳光药业有限公司	Dérivés hexahydropentaléno, leur procédé de préparation et leur utilisation en médecine
TWI500613B (zh)	2012-10-17	2015-09-21	Cadila Healthcare Ltd	新穎之雜環化合物
IN2015DN03795A (fr)	2012-10-24	2015-10-02	Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2014074668A1 (fr)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
WO2015090224A1 (fr) *	2013-12-20	2015-06-25	中国人民解放军军事医学科学院毒物药物研究所	Nouveau composé pipéridine carboxamide, procédé de préparation et utilisation associée
WO2015128453A1 (fr)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Utilisation médicale d'un inhibiteur de dpp-4
CN104529856A (zh) *	2015-01-13	2015-04-22	佛山市赛维斯医药科技有限公司	一种硝基金刚烷酰胺衍生物、其制备方法和用途
CN104529858A (zh) *	2015-01-13	2015-04-22	佛山市赛维斯医药科技有限公司	含卤代金刚烷和酰胺类衍生物、其制备方法和用途
WO2016128343A1 (fr) *	2015-02-09	2016-08-18	F. Hoffmann-La Roche Ag	Composés pour le traitement d'un cancer
EP3053577A1 (fr) *	2015-02-09	2016-08-10	F. Hoffmann-La Roche AG	Composés pour le traitement du cancer
WO2016138908A1 (fr)	2015-03-03	2016-09-09	Saniona A/S	Formulation à base de combinaison de tésofensine et de bêta-bloquant
KR20180006881A (ko)	2015-03-09	2018-01-19	인테크린 테라퓨틱스, 아이엔씨.	비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
US10426818B2 (en)	2015-03-24	2019-10-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Method and pharmaceutical composition for use in the treatment of diabetes
CA2990460C (fr)	2015-07-02	2023-10-17	Centrexion Therapeutics Corporation	Citrate de (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
WO2018162722A1 (fr)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
EP3461819B1 (fr)	2017-09-29	2020-05-27	Probiodrug AG	Inhibiteurs de la glutaminyl-cyclase
EP3723753A4 (fr)	2017-12-15	2022-01-26	Praxis Biotech LLC	Inhibiteurs de la protéine d'activation des fibroblastes
CN118955353A (zh) *	2024-10-14	2024-11-15	南京恒远科技开发有限公司	一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2004A (en) *		1841-03-12		Improvement in the manner of constructing and propelling steam-vessels
US2005A (en) *		1841-03-16		Improvement in the manner of constructing molds for casting butt-hinges
US3225037A (en)	1959-03-30	1965-12-21	Sterling Drug Inc	10-[(amino- and acylamino-1-piperidyl) lower-alkyl]-phenothiazines
GB1460389A (en) *	1974-07-25	1977-01-06	Pfizer Ltd	4-substituted quinazoline cardiac stimulants
US4302455A (en) *	1980-04-14	1981-11-24	Merck & Co., Inc.	2-(4-Aminopiperidino)pyrazines
US5001125A (en)	1984-03-26	1991-03-19	Janssen Pharmaceutica N.V.	Anti-virally active pyridazinamines
JP2869561B2 (ja) *	1989-05-22	1999-03-10	大塚製薬株式会社	血小板粘着抑制剤
CA2106840A1 (fr) *	1992-09-25	1994-03-26	Marco Baroni	Heteroarylazetidines et -pyrrolidines, methode pour les preparer et compositions pharmaceutiques les renfermant
ES2079323B1 (es) *	1994-06-21	1996-10-16	Vita Invest Sa	Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
UA51716C2 (uk) *	1996-07-08	2002-12-16	Авентіс Фармасьютікалз Продактс Інк.	Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
FR2780057B1 (fr)	1998-06-18	2002-09-13	Sanofi Sa	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
CZ20014127A3 (cs) *	1999-05-21	2002-06-12	Abbott Laboratories	Heterocyklické substituované aminoazacykly uľitečné jako prostředky ovlivňující centrální nervový systém
TW583185B (en) *	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
AU2001277754B2 (en)	2000-08-10	2005-09-29	Mitsubishi Tanabe Pharma Corporation	Proline derivatives and use thereof as drugs
TWI290919B (en) *	2000-10-06	2007-12-11	Tanabe Seiyaku Co	Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JP2002264450A (ja) *	2000-12-21	2002-09-18	Ricoh Co Ltd	画像処理ユニット、画像形成装置、画像形成方法及び画像処理システム
US20040180925A1 (en) *	2000-12-27	2004-09-16	Kenji Matsuno	Dipeptidylpeptidase-IV inhibitor
GB0115517D0 (en) *	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
ATE370943T1 (de) *	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
CN1990469A (zh) *	2001-06-27	2007-07-04	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
AU2003279368A1 (en)	2002-06-20	2004-01-06	Akzo Nobel N.V.	(stabilised) peroxide compositions phlegmatised with a specific unsaturated phlegmatising agent
TW200401635A (en)	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
CN1706726A (zh) *	2004-02-17	2005-12-14	梅加特雷德国际公司	带发光部件的容器

2002
- 2002-03-06 HU HU0200849A patent/HUP0200849A2/hu unknown
2003
- 2003-03-04 JP JP2003572969A patent/JP4559737B2/ja not_active Expired - Fee Related
- 2003-03-04 WO PCT/HU2003/000017 patent/WO2003074500A2/fr not_active Ceased
- 2003-03-04 EA EA200401157A patent/EA007410B1/ru not_active IP Right Cessation
- 2003-03-04 US US10/507,005 patent/US7348327B2/en not_active Expired - Fee Related
- 2003-03-04 AU AU2003209514A patent/AU2003209514B2/en not_active Ceased
- 2003-03-04 AT AT03743452T patent/ATE443054T1/de not_active IP Right Cessation
- 2003-03-04 MX MXPA04008613A patent/MXPA04008613A/es active IP Right Grant
- 2003-03-04 HR HR20040910A patent/HRP20040910A2/hr not_active Application Discontinuation
- 2003-03-04 EP EP03743452A patent/EP1487807B1/fr not_active Expired - Lifetime
- 2003-03-04 PL PL03371099A patent/PL371099A1/xx not_active Application Discontinuation
- 2003-03-04 KR KR1020047013870A patent/KR100977898B1/ko not_active Expired - Fee Related
- 2003-03-04 BR BR0307960-0A patent/BR0307960A/pt not_active IP Right Cessation
- 2003-03-04 CN CNA038052636A patent/CN1639159A/zh active Pending
- 2003-03-04 CN CNA2006101640208A patent/CN1990486A/zh active Pending
- 2003-03-04 DE DE60329282T patent/DE60329282D1/de not_active Expired - Lifetime
- 2003-03-04 CA CA2475312A patent/CA2475312C/fr not_active Expired - Fee Related
- 2003-03-04 NZ NZ535662A patent/NZ535662A/en unknown
- 2003-03-04 RS YU79004A patent/RS79004A/sr unknown
- 2003-03-05 AR ARP030100723A patent/AR038868A1/es unknown
- 2003-03-06 TW TW092104743A patent/TWI250978B/zh not_active IP Right Cessation
- 2003-04-03 UA UA20041008080A patent/UA78291C2/uk unknown
2004
- 2004-07-29 IL IL163286A patent/IL163286A/en not_active IP Right Cessation
- 2004-07-29 MA MA27806A patent/MA27105A1/fr unknown
- 2004-07-29 TN TNP2004000141A patent/TNSN04141A1/en unknown
- 2004-08-13 ZA ZA200406467A patent/ZA200406467B/en unknown
- 2004-09-02 IS IS7434A patent/IS7434A/is unknown
- 2004-09-03 EC EC2004005274A patent/ECSP045274A/es unknown
- 2004-10-05 NO NO20044221A patent/NO20044221L/no not_active Application Discontinuation
2006
- 2006-09-07 IL IL177933A patent/IL177933A0/en unknown
2008
- 2008-03-05 US US12/042,595 patent/US7655663B2/en not_active Expired - Fee Related
2010
- 2010-02-01 US US12/697,762 patent/US8063045B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA04008613A (es)	2005-06-08
US8063045B2 (en)	2011-11-22
AR038868A1 (es)	2005-02-02
ATE443054T1 (de)	2009-10-15
HUP0200849D0 (fr)	2002-05-29
JP2005529078A (ja)	2005-09-29
WO2003074500A2 (fr)	2003-09-12
CN1639159A (zh)	2005-07-13
AU2003209514A1 (en)	2003-09-16
AU2003209514B2 (en)	2009-07-16
IS7434A (is)	2004-09-02
US7655663B2 (en)	2010-02-02
KR100977898B1 (ko)	2010-08-24
ZA200406467B (en)	2005-06-22
ECSP045274A (es)	2004-10-26
EP1487807A2 (fr)	2004-12-22
HUP0200849A2 (hu)	2004-08-30
EA200401157A1 (ru)	2005-06-30
EA007410B1 (ru)	2006-10-27
US20100210838A1 (en)	2010-08-19
BR0307960A (pt)	2005-02-15
CN1990486A (zh)	2007-07-04
TWI250978B (en)	2006-03-11
JP4559737B2 (ja)	2010-10-13
US7348327B2 (en)	2008-03-25
PL371099A1 (en)	2005-06-13
KR20040091102A (ko)	2004-10-27
NO20044221L (no)	2004-12-06
EP1487807B1 (fr)	2009-09-16
WO2003074500A3 (fr)	2003-12-18
DE60329282D1 (de)	2009-10-29
US20080161310A1 (en)	2008-07-03
HRP20040910A2 (en)	2006-02-28
IL177933A0 (en)	2006-12-31
CA2475312C (fr)	2011-10-18
IL163286A (en)	2007-06-03
NZ535662A (en)	2007-05-31
UA78291C2 (en)	2007-03-15
CA2475312A1 (fr)	2003-09-12
RS79004A (sr)	2006-12-15
TW200303860A (en)	2003-09-16
US20050130981A1 (en)	2005-06-16
TNSN04141A1 (en)	2007-03-12

Publication	Publication Date	Title
MA27105A1 (fr)	2004-12-20	Nouveaux composes
MA26216A1 (fr)	2004-07-01	Nouveaux composes
DE602004018654D1 (de)	2009-02-05	Se
ATE427876T1 (de)	2009-04-15	Luftkissenboot
ATE318817T1 (de)	2006-03-15	Aza-arylpiperazine
NO20044046L (no)	2004-11-15	Substituerte hydroksyetylaminer
MA28933B1 (fr)	2007-10-01	Nouveaux composes
DE60326590D1 (de)	2009-04-23	Tend lamotrigin
NO20052239D0 (no)	2005-05-06	Fast preparat
ATE349458T1 (de)	2007-01-15	Etonogestrelester
ATE496887T1 (de)	2011-02-15	Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
ATA1572002A (de)	2003-06-15	Managementspleisskassette
NO20034599L (no)	2005-04-15	Brokonstruksjon
ATA4142004A (de)	2005-12-15	Trägerverbau
ATE444953T1 (de)	2009-10-15	Substituierte spirobenzazepine
NO20034600D0 (no)	2003-10-14	Brokonstruksjon
EP1658301A4 (fr)	2009-12-09	Composes n-desmethyl-11-desoxyerythromycine-n-substitues
ATA19152002A (de)	2004-11-15	Hubkupplung
EP1635834A4 (fr)	2009-12-02	Nouveaux composes
FI20021381L (fi)	2004-01-13	Kaivo
FR2840006B1 (fr)	2005-01-21	Construction demontable
ATE350379T1 (de)	2007-01-15	Substituierte benzdioxepine
ITGE20020039A0 (it)	2002-05-15	Bicicletta
ATA16872002A (de)	2005-06-15	Zwischenstück
AT5889U3 (de)	2003-04-25	Brennholzspleisser